Hydromorphone hydrochloride
Synonym(s):(5α)-4,5-Epoxy-3-hydroxy-17-methyl-morphinan-6-one hydrochloride;Hydromorphone HCl
- CAS NO.:71-68-1
- Empirical Formula: C17H20ClNO3
- Molecular Weight: 321.8
- MDL number: MFCD03427563
- EINECS: 200-762-6
- SAFETY DATA SHEET (SDS)
- Update Date: 2023-06-08 09:02:58
What is Hydromorphone hydrochloride?
Description
Hydromorphone hydrochloride is a pure opioid agonist with the principal therapeutic activity of analgesia. It has an analgesic potency approximately two to eight times greater than that of morphine and has a rapid onset of action. A significant feature of the analgesia is that it can occur without loss of consciousness.
Chemical properties
White Solid
The Uses of Hydromorphone hydrochloride
Analgesic (narcotic). Preparation by electrolytic reduction of Morphine. Controlled substance (opiate).
Biochem/physiol Actions
Narcotic opiate analgesic; μ opioid receptor agonist.
Clinical Use
Hydromorphone is a potent μ agonist (eight times greater than morphine) that is used to treat severe pain. It is available in intramuscular, intravenous, subcutaneous, oral, and rectal dosage forms. Like all strong μ agonists, hydromorphone is addicting and is a Schedule II drug. Hydromorphone has an oral:parenteral potency ratio of 5:1. The plasma half-lives after parenteral and oral dosage are 2.5 and 4 hours, respectively.
Safety Profile
Poison by subcutaneous and intravenous routes. Experimental teratogenic effects. A powerful analgesic. When heated to decomposition it emits very toxic fumes of NOx and HCl. See also MORPHINE.
Drug interactions
Potentially hazardous interactions with other drugs
Alcohol: can cause dose dumping with sustained
release preparations.
Analgesics: possible opioid withdrawal effects with
buprenorphine and pentazocine.
Antidepressants: possible CNS excitation or
depression with MAOIs - avoid concomitant use
and for 2 weeks after stopping MAOI; possible
CNS excitation or depression with moclobemide;
increased sedative effects with tricyclics.
Antihistamines: increased sedative effects with
sedating antihistamines.
Antipsychotics: enhanced hypotensive and sedative
effects.
Dopaminergics: avoid with selegiline.
Nalmefene: avoid concomitant use.
Sodium oxybate: enhanced effect of sodium oxybate
- avoid.
Metabolism
Hydromorphone undergoes extensive firstpass metabolism. It is extensively metabolised by glucuronidation in the liver and excreted in the urine mainly as conjugated hydromorphone, dihydroisomorphine, and dihydromorphine.
Properties of Hydromorphone hydrochloride
Melting point: | >280°C (dec.) |
alpha | D25 -133° |
Density | 1.1451 (rough estimate) |
refractive index | 1.6470 (estimate) |
storage temp. | 2-8°C |
solubility | H2O: >10 mg/mL |
form | A crystalline solid |
EPA Substance Registry System | Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, hydrochloride (1:1), (5.alpha.) (71-68-1) |
Safety information for Hydromorphone hydrochloride
Signal word | Warning |
Pictogram(s) |
Exclamation Mark Irritant GHS07 |
GHS Hazard Statements |
H302:Acute toxicity,oral H336:Specific target organ toxicity,single exposure; Narcotic effects |
Computed Descriptors for Hydromorphone hydrochloride
Abamectin manufacturer
Ralington Pharma
New Products
4-Aminotetrahydropyran-4-carbonitrile Hydrochloride (R)-3-Aminobutanenitrile Hydrochloride 4-AMINO-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HCL 4-(Dimethylamino)tetrahydro-2H-pyran-4-carbonitrile 3-((Dimethylamino)methyl)-5-methylhexan-2-one oxalate 1,4-Dioxa-8-azaspiro[4.5]decane 5-Bromo-2-nitropyridine Nimesulide BP Aceclofenac IP/BP/EP Diclofenac Sodium IP/BP/EP/USP Mefenamic Acid IP/BP/EP/USP Ornidazole IP Diclofenac Potassium SODIUM AAS SOLUTION ZINC AAS SOLUTION BUFFER SOLUTION PH 10.0(BORATE) GOOCH CRUCIBLE SINTERED AQUANIL 5 BERYLLIUM AAS SOLUTION 2-Bromo-1-(bromomethyl)-3-chloro-5-nitrobenzene 2-Bromo-3-nitroaniline N-(3-Hydroxypropyl)-N-methylacetamide 3-Bromo-6-chloropyridazine 4-ethyl-3-nitrobenzoic acidRelated products of tetrahydrofuran
You may like
-
71-68-1 Hydromorphone hydrochloride 98%View Details
71-68-1 -
1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%View Details
99903-60-3 -
1823368-42-8 98%View Details
1823368-42-8 -
2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%View Details
1307449-08-6 -
Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%View Details
25408-95-1 -
2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%View Details
1805639-70-6 -
1784294-80-9 98%View Details
1784294-80-9 -
Lithium ClavulanateView Details
61177-44-4